FDA Moves to Revoke Approval for Rare Disease Drug Tavneos After Data Scandal
The Food and Drug Administration is seeking the market withdrawal of Tavneos, a vasculitis treatment, following allegations of data manipulation. As reported by Ars Technica, the regulator now questions the drug’s efficacy while citing risks of fatal liver injury, sparking a legal and regulatory battle between the agency and pharmaceutical giant Amgen.
Context from Industry Pulse
The Tavneos dispute underscores the vulnerability of the regulatory process when small biotechnology firms conduct pivotal trials for orphan drugs. Since many rare disease treatments lack large-scale comparative studies, the FDA often relies on narrow advisory committee votes. The acquisition of ChemoCentryx by Amgen further complicated the landscape, as a major pharmaceutical player now defends a revenue stream that reached nearly 500 million dollars despite the retraction of the drug's primary clinical paper. The divergence between the United States, which is currently in a legal stalemate, and the European Union, which has already removed the drug, highlights the complexity of reversing federal approvals once a high-cost therapy becomes an established clinical option.
The regulatory controversy surrounding Tavneos began with its narrow approval in October 2021. According to Ars Technica, the medication was designed to treat a rare autoimmune condition known as ANCA-associated vasculitis, which causes the immune system to attack blood vessels and can lead to organ failure. While patients and some physicians initially supported the drug as a way to reduce dependency on steroids, the original study design faced criticism from an independent advisory committee for lacking clarity and verification.
Following the drug’s release, the manufacturer ChemoCentryx was purchased by Amgen. Despite the treatment generating nearly half a billion dollars in sales during the 2025 fiscal year, legal proceedings against the original developer uncovered evidence of data manipulation. Ars Technica reports that these revelations led the New England Journal of Medicine to retract the pivotal clinical trial paper earlier this year, while regulators in the European Union and the United Kingdom have already moved to pull the product from their respective markets.
In the United States, the Food and Drug Administration issued a formal proposal for withdrawal in April, arguing that the treatment no longer meets the standard for substantial evidence of effectiveness. The agency also highlighted reports of serious liver damage associated with the medication. However, Amgen is currently contesting the withdrawal, submitting a lengthy defense to the agency claiming that the totality of evidence still supports the drug remaining available to patients who suffer from this life-threatening condition.
The standoff highlights ongoing difficulties for regulators tasked with overseeing drugs approved based on limited or questionable data. As Ars Technica notes, the high cost of the treatment, which reaches approximately 220,000 dollars annually, adds a significant financial dimension to the dispute. While a 69 million dollar settlement for an investor lawsuit is under consideration by the courts, the final status of the drug in the American market remains unresolved as experts debate the integrity of the initial approval process.
The Industry Pulse Bottom Line
The FDA’s struggle to withdraw Tavneos reveals the limitations of post-market safeguards. When clinical data integrity is compromised, the agency faces significant legal hurdles to remove high-revenue treatments despite concerns over efficacy and patient safety.